

CURRICULUM VITAE

Kristen Harris Nwanyanwu, MD, MBA, MHS

Version Date: 2/7/2025

Contact Information:

Address 40 Temple Street
New Haven, CT 06510
Phone: 1 (475) 441-0387
Email: k.nwanyanwu@yale.edu

School: Yale School of Medicine

Education:

xxxx - 05/2009 MBA, The Wharton School, Philadelphia, PA
xxxx - 05/2009 MD, University of Pennsylvania School of Medicine, Philadelphia, PA
xxxx - 05/2020 MHS, Yale University, Health Science, New Haven, CT

Career/Academic Appointments:

06/2010 Transitional Internship, Internal Medicine, Albert Einstein Medical Center, Philadelphia, PA
06/2013 Ophthalmology Residency, Ophthalmology, Kellogg Eye Center, University of Michigan, Ann Arbor, MI
06/2015 Vitreoretinal Surgery Fellowship, Ophthalmology and Visual Sciences, Illinois Eye and Ear Infirmary, University of Illinois at Chicago, Chicago, IL
08/2015 - 06/2022 Assistant Professor, Ophthalmology and Visual Science, Yale School of Medicine, New Haven, CT
07/2022 - 06/2027 Associate Professor on Term, Ophthalmology and Visual Science, Yale School of Medicine, New Haven, CT
07/2023 - 06/2027 Associate Professor on Term, Biomedical Informatics and Data Science, Yale School of Medicine, New Haven, CT
07/2024 - 12/2024 Associate Professor on Term, Management, Yale School of Medicine, New Haven, CT

Administrative Positions:

2024 - Present Associate Director of Community Engaged Research and Participant Recruitment, Yale Center for Clinical Investigation (YCCI), Yale School of Medicine, New Haven, CT

Professional Honors & Recognition:

International/National/Regional

2023	Young Alumni Service Award, University of Pennsylvania Perelman School of Medicine
2023	Secretariat Award, American Academy of Ophthalmology
2023	Director's Award, National Eye Institute
2024	Scientific Award, National Medical Association Ophthalmology Section
2024	Leadership Development Program, American Academy of Ophthalmology - American Society of Retinal Specialists
2025	AOA, AOA Beta Chapter at the University of Pennsylvania School of Medicine
2025	Member Retina Society, Retina Society

Yale University/Yale School of Medicine/Hospital System

2024	Orthwein Scholar, Yale School of Medicine
------	---

Grants/Clinical Trials History:

Current Grants

Agency:	NIH
I.D.#:	KNWANYANWU
Title:	T1CARE grant (Addressing Social Determinants of Health in Young Adults with Type 1 Diabetes Through Comprehensive Assessment, Responsiveness, and Engagement)
P.I.:	Kasia Lipska
Role:	Consultant
Percent effort:	N/A
Total costs:	\$2,500,000.00
Project period:	02/01/2025 - 01/01/2030

Current Clinical Trials

Agencies:	Yale University School of Medicine
I.D.#:	2000030972
Title:	Diabetic retinopathy: Early detection using home detection methods and their efficacy
P.I.:	Kristen Harris Nwanyanwu
Role:	Principal Investigator
Percent effort:	N/A
Total costs:	-
Project period:	03/05/2018 - ongoing
Agencies:	National Eye Institute
I.D.#:	2000031731
Title:	Sight-saving Engagement and Evaluation in New Haven (SEEN) Program

P.I.: Kristen Harris Nwanyanwu
Role: Principal Investigator
Percent effort: N/A
Total costs: -
Project period: 01/13/2022 - ongoing

Past Grants

Agency: National Eye Institute (NIH)
I.D.#: 1 K23 EY030530-01
Title: Undiagnosed Diabetic Retinopathy: Using Participatory Science to Design an Intervention for Patients at High-Risk for Blindness
Role: Principal Investigator
Percent effort: 75%
Total costs: \$1,272,085.00
Project period: 09/01/2019 - 08/31/2024

Agency: National Eye Institute
I.D.#: K23EY030530
Title: Undiagnosed Diabetic Retinopathy: Using Participatory Science to Design an Intervention for Patients at High-Risk for Blindness
P.I.: Kristen Harris Nwanyanwu
Role: PI
Percent effort: N/A
Total costs: -
Project period: 09/01/2019 - 08/31/2024

Past Clinical Trials

Agencies: BioMed Valley Discoveries, Inc.
I.D.#: 1303011687
Title: Phase I Dose Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients with Advanced Malignancies
P.I.: Mario Sznol
Role: Sub-Investigator
Percent effort: N/A
Total costs: -
Project period: 08/02/2013 - 02/08/2018

Agencies: Celgene Corporation
I.D.#: 1312013122
Title: Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma
P.I.: Iris Isufi
Role: Sub-Investigator

Percent effort:	N/A
Total costs:	-
Project period:	05/07/2014 - 01/13/2021
Agencies:	Southwest Oncology Group (SWOG)
I.D.#:	1405014058
Title:	Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer
P.I.:	Roy S. Herbst
Role:	Sub-Investigator
Percent effort:	N/A
Total costs:	-
Project period:	06/12/2014 - 10/05/2023
Agencies:	Karyopharm Therapeutics, Inc.
I.D.#:	1411014855
Title:	Selinexor (KPT-330) in Older Patients With Relapsed AML (SOPRA)
Role:	Sub-Investigator
Percent effort:	N/A
Total costs:	15580.0000
Project period:	05/15/2015 - 03/28/2018
Agencies:	AbbVie, Inc.
I.D.#:	1511016810
Title:	A Randomized, Placebo Controlled Phase 2b/3 Study of ABT-414 With Concurrent Chemoradiation and Adjuvant Temozolomide in Subjects With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification (Intelligence 1)
P.I.:	Joseph N. Contessa
Role:	Sub-Investigator
Percent effort:	N/A
Total costs:	-
Project period:	02/25/2016 - 10/24/2019
Agencies:	Hoffmann (F) - La Roche, Ltd
I.D.#:	1604017550
Title:	A Phase III Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma
P.I.:	Jeremy Kortmansky
Role:	Sub-Investigator
Percent effort:	N/A
Total costs:	-
Project period:	08/03/2016 - 02/08/2019

Agencies: Yale University School of Medicine
 I.D.#: 1608018321MRR
 Title: Geospatial analysis of environments of patients with diabetic eye disease
 P.I.: Kristen Harris Nwanyanwu
 Role: Principal Investigator
 Percent effort: N/A
 Total costs: -
 Project period: 11/14/2016 - 11/15/2017

Agencies: Bayer Healthcare Pharmaceuticals, Inc.
 I.D.#: 2000020826
 Title: Phase 1b Multi-indication Study of Anetumab Ravtansine (BAY94-9343) in Patients With Mesothelin Expressing Advanced or Recurrent Malignancies
 Role: Sub-Investigator
 Percent effort: N/A
 Total costs: -
 Project period: 08/21/2017 - 11/26/2018

Agencies: Clinical and Translational Science Award (CTSA)
 I.D.#: 2000022210MRR
 Title: Geospatial analysis of environments of patients with eye disease
 P.I.: Kristen Harris Nwanyanwu
 Role: Principal Investigator
 Percent effort: N/A
 Total costs: -
 Project period: 02/10/2018 - 03/15/2019

Agencies: Yale University School of Medicine
 I.D.#: 2000023866
 Title: Exploring the Cytokine Profiles in Tears and Vitreous Fluid
 P.I.: Luciano V. Del Priore
 Role: Sub-Investigator
 Percent effort: N/A
 Total costs: -
 Project period: 10/02/2018 - 10/14/2021

Pending Clinical Trials

Agencies: National Eye Institute
 I.D.#: 2000027927MRR
 Title: Validation of a Risk Score to Predict Diabetic Retinopathy Progression
 P.I.: Kristen Harris Nwanyanwu
 Role: Principal Investigator
 Percent effort: N/A

Total costs:	-
Project period:	04/17/2020 - ongoing
Agencies:	National Eye Institute
I.D.#:	2000027573EXEMPT
Title:	Factors Influencing the Receipt of Diabetic Retinopathy Screening in a High-Risk Population
P.I.:	Kristen Harris Nwanyanwu
Role:	Principal Investigator
Percent effort:	N/A
Total costs:	-
Project period:	10/26/2020 - ongoing
Agencies:	National Eye Institute
I.D.#:	2000034067
Title:	Identifying risk factors associated with loss to follow-up in adults being treated with anti-VEGF injections and/or PRP for diabetic retinopathy
P.I.:	Kristen Harris Nwanyanwu
Role:	Principal Investigator
Percent effort:	N/A
Total costs:	-
Project period:	11/29/2022 - ongoing
Agencies:	National Eye Institute
I.D.#:	2000034443
Title:	SEEN Retrospective Medical Record Review
P.I.:	Kristen Harris Nwanyanwu
Role:	Principal Investigator
Percent effort:	N/A
Total costs:	-
Project period:	01/29/2023 - ongoing

Invited Speaking Engagements, Presentations & Workshops Not Affiliated With Yale:

International/National

1. "Health Equity in Diabetic Retinopathy: Addressing Health Disparities to End Preventable Blindness". Visiting Professorship, Wilmer - Johns Hopkins University , July 2021. (Lecture)
2. "Designing Better Systems to Advance Equity in Diabetic Retinopathy". Visiting Professor, San Francisco, CA, March 2024. (Lecture)
3. "Toward a Framework to Improve Diversity and Inclusion in Clinical Trials". National Academies of Sciences, Engineering, and Medicine, Washington, DC, May 2024. (Other)
4. "The How of Health Equity: DR at the Margins". Grand Rounds, Boston, MA, May 2024. (Lecture)
5. "Participatory Science to Advance Equity in Diabetic Retinopathy". Visiting Professor, Columbus, OH, June 2024. (Lecture)

6. "Interventions for social determinants of health in diabetic retinopathy". Retina World Congress, International Webinar, July 2024. (Lecture)
7. "Vision Research and Citizen Scientist". Prevent Blindness 13th Annual Focus on Eye Health Summit, Webinar, July 2024. (Oral Presentation)
8. "Women in Retina Mentoring Symposium". American Society of Retinal Specialists , Stockholm, Stockholm County, July 2024. (Other)
9. "Retina Cafe". American Academy of Ophthalmology, Chicago, IL, October 2024. (Other)
10. "Eradicate TRD". Envision Conference, San Juan, San Juan, February 2025. (Lecture)
11. "Visionary Courage: Journey of a Health Equity Ophthalmologist". Alpha Omega Alpha University of Pennsylvania , Philadelphia, PA, March 2025. (Address)

Regional

1. "Multi-Method Approach to advance Health Equity in Diabetic Retinopathy". Grand Rounds Cornell University , New York, NY, December 2022. (Lecture)
2. "Eradicate TRD: A multi-method approach to decreasing preventable blindness from diabetes-related eye disease". NYU Department of Ophthalmology , Grand Rounds Speaker , New York, NY, November 2024. (Lecture)

Peer-Reviewed Presentations Given at Meetings Not Affiliated With Yale:

International/National

1. **Harris Nwanyanwu K** . Sight-Saving Engagement and Evaluation in New Haven (SEEN) Program Identifies and Addresses Adverse Social Determinants in Individuals at High Risk for Blindness. Retina Society , Lisbon, Lisbon, September 2024. (Oral Presentation)

Professional Service:

Peer Review Groups/Grant Study Sections

2021 - Present Reviewer, Early Career Reviewer, Pathophysiology of Eye Disease, Special Emphasis Panel, Scientific Review Group, NIH/NEI

Advisory Boards

2021 - Present Member, Medical Alumni Affairs Council, University of Pennsylvania
2022 Member, Membership Advisory Group, American Diabetes Association
2024 Member, Focus on Diabetes Program: Communicating the Risk of Vision Loss and Effective Prevention Strategies, American Diabetes Association
2024 - Present Advisor, Eye Health Advisory Group , American Diabetes Association

Journal Services

Editorial boards

2022 - Present Editorial Board Member, Translational Vision Science and Technology

Professional Organizations

American Academy of Ophthalmology Taskforce on Disparities in Eyecare: Sub-Taskforce on Leveraging Data

2021 - 2022 Member, American Academy of Ophthalmology Taskforce on Disparities in Eyecare: Sub-Taskforce on Leveraging Data

American Academy of Ophthalmology Taskforce on Expanding Access to Care in Federally Qualified Health Centers

2022 - Present Member, American Academy of Ophthalmology Taskforce on Expanding Access to Care in Federally Qualified Health Centers

Penn Med Black Alumni Society

2020 - Present Founding Member, Penn Med Black Alumni Society

Yale University / Hospital System

Medical School

2021 - 2024 Faculty Member, Dean's Faculty Advisory Council
2022 - 2024 Executive Committee Member, Dean's Faculty Advisory Council
2022 - Present Executive Committee Member, Minority Organization for Retention and Expansion

Public Service / Media Presence

Public Service

2022 - Present Board Member, Neighborhood Music School

Bibliography:

Peer-Reviewed Original Research

1. **Nwanyanwu KH** , Comer G, Demirci H. Presumed choroidal metastasis secondary to clear cell sarcoma of the right knee. *International Ophthalmology* 2012, 33: 163-165. [PMID: 23053771](#) , [DOI: 10.1007/s10792-012-9642-1](#) .
2. **Harris Nwanyanwu KM** , De Lott LB, Cornblath WT, Elner VM. Transient monocular vision loss due to churg-strauss syndrome vasculitis. *JAMA Ophthalmology* 2013, 131: 117-9. [PMID: 23307226](#) , [DOI: 10.1001/jamaophthalmol.2013.576](#) .
3. Stein JD, Newman-Casey PA, Kim DD, **Nwanyanwu KH** , Johnson MW, Hutton DW. Cost-Effectiveness of Various Interventions for Newly Diagnosed Diabetic Macular Edema. *Ophthalmology* 2013, 120: 1835-1842. [PMID: 23642372](#) , [PMCID: PMC3737388](#) , [DOI: 10.1016/j.ophtha.2013.02.002](#) .
4. **Nwanyanwu K** , Talwar N, Gardner TW, Wrobel JS, Herman WH, Stein JD. Predicting Development of Proliferative Diabetic Retinopathy. *Diabetes Care* 2013, 36: 1562-1568. [PMID: 23275374](#) , [PMCID: PMC3661803](#) , [DOI: 10.2337/dc12-0790](#) .

5. **Nwanyanwu KH** , Lim JI. Smudge in My Vision. JAMA Ophthalmology 2013, 131: 1637-1638. [PMID: 24337560](#) , [DOI: 10.1001/jamaophthalmol.2013.7410](#) .
6. Schneider EW, Mruthyunjaya P, Talwar N, **Nwanyanwu K** , Nan B, Stein JD. Reduced Fluorescein Angiography and Fundus Photography Use in the Management of Neovascular Macular Degeneration and Macular Edema During the Past Decade. Imaging Tests for Macular Diseases. Investigative Ophthalmology & Visual Science 2014, 55: 542-549. [PMID: 24346174](#) , [PMCID: PMC3907135](#) , [DOI: 10.1167/iovs.13-13034](#) .
7. **Nwanyanwu KH** , Newman-Casey PA, Gardner TW, Lim JI. Beyond HbA1c: Environmental Risk Factors for Diabetic Retinopathy. Journal Of Clinical & Experimental Ophthalmology 2015, 06: 405. [PMID: 26973797](#) , [PMCID: PMC4785841](#) , [DOI: 10.4172/2155-9570.1000405](#) .
8. Alasil T, Ketner S, Coady PA, Adelman RA, **Nwanyanwu KH** . Idiopathic retinal vasculitis, aneurysms and neuroretinitis case report. American Journal Of Ophthalmology Case Reports 2016, 2: 33-36. [PMID: 29503895](#) , [PMCID: PMC5757360](#) , [DOI: 10.1016/j.ajoc.2016.04.006](#) .
9. Hussnain SA, Ketner S, Coady PA, Kombo N, **Nwanyanwu K** . Ocular Syphilis Presenting as Bilateral Acute Retinal Necrosis in an Immunocompetent Host. Connecticut Medicine 2016, 80: 533-536. [PMID: 29772137](#) .
10. **Nwanyanwu KH** , Nardini H, Shaughness G, Nunez-Smith M, Newman-Casey PA. Systematic review of community-engaged research in ophthalmology. Expert Review Of Ophthalmology 2017, 12: 233-241. [PMID: 29333193](#) , [PMCID: PMC5759339](#) , [DOI: 10.1080/17469899.2017.1311787](#) .
11. Hall LB, **Nwanyanwu K** . Spontaneous Rupture of an Iris Stromal Cyst. Ophthalmology 2018, 125: 30. [PMID: 29268865](#) , [DOI: 10.1016/j.ophtha.2017.09.005](#) .
12. Linderman W, Apostolopoulos N, Gopal A, Encandela J, Teng C, **Nwanyanwu K** , Forster S. Near-Peer Teaching Outreach Programs to Increase Minority Physician Recruitment. Journal Of Academic Ophthalmology 2018, 10: e122-e126. [DOI: 10.1055/s-0038-1667202](#) .
13. **Nwanyanwu K** , Nunez-Smith M, Desai M, Gardner T. 2458 Determining the prevalence and associated multilevel characteristics of undiagnosed diabetic retinopathy. Journal Of Clinical And Translational Science 2018, 2: 67-68. [PMCID: PMC6799117](#) , [DOI: 10.1017/cts.2018.247](#) .
14. Williams BK, Welch R, **Nwanyanwu KH** , Shields CL. Hemorrhagic occlusive retinal vasculitis leading to the diagnosis of ciliary body melanoma. Saudi Journal Of Ophthalmology 2018, 33: 81-83. [PMID: 30930668](#) , [PMCID: PMC6424716](#) , [DOI: 10.1016/j.sjopt.2018.09.004](#) .
15. Fairless E, **Nwanyanwu K** . Barriers to and Facilitators of Diabetic Retinopathy Screening Utilization in a High-Risk Population. Journal Of Racial And Ethnic Health Disparities 2019, 6: 1244-1249. [PMID: 31463812](#) , [PMCID: PMC6880869](#) , [DOI: 10.1007/s40615-019-00627-3](#) .
16. Yusuf R, Chen EM, **Nwanyanwu K** , Richards B. Neighborhood Deprivation and Adherence to Initial Diabetic Retinopathy Screening. Ophthalmology Retina 2020, 4: 550-552. [PMID: 32139294](#) , [PMCID: PMC8281953](#) , [DOI: 10.1016/j.oret.2020.01.016](#) .
17. Chen EM, Kombo N, Teng CC, Mruthyunjaya P, **Nwanyanwu K** , Parikh R. Ophthalmic Medication Expenditures and Out-of-Pocket Spending An Analysis of United States Prescriptions from 2007 through 2016. Ophthalmology 2020, 127: 1292-1302. [PMID: 32359935](#) , [PMCID: PMC7508869](#) , [DOI: 10.1016/j.ophtha.2020.04.037](#) .
18. Chen EM, Ahluwalia A, Parikh R, **Nwanyanwu K** . Ophthalmic Emergency Department Visits: Factors Associated With Loss to Follow-up. American Journal Of Ophthalmology 2020, 222: 126-136. [PMID: 32882220](#) , [PMCID: PMC8328190](#) , [DOI: 10.1016/j.ajo.2020.08.038](#) .

19. Fairless EA, **Nwanyanwu KH**, Forster SH, Teng CC. Ophthalmology Departments Remain Among the Least Diverse Clinical Departments at United States Medical Schools. *Ophthalmology* 2021, 128: 1129-1134. [PMID: 33440211](#), [PMCID: PMC8328189](#), [DOI: 10.1016/j.ophtha.2021.01.006](#).
20. Chen EM, Andoh JE, **Nwanyanwu K**. Socioeconomic and Demographic Disparities in the Use of Telemedicine for Ophthalmic Care during the COVID-19 Pandemic. *Ophthalmology* 2021, 129: 15-25. [PMID: 34245753](#), [PMCID: PMC8415734](#), [DOI: 10.1016/j.ophtha.2021.07.003](#).
21. Nwanyanwu KMJH, Nunez-Smith M, Gardner TW, Desai MM. Awareness of Diabetic Retinopathy: Insight From the National Health and Nutrition Examination Survey. *American Journal Of Preventive Medicine* 2021, 61: 900-909. [PMID: 34426057](#), [PMCID: PMC8608699](#), [DOI: 10.1016/j.amepre.2021.05.018](#).
22. Scott AW, Elam AR, **Nwanyanwu K**. Addressing Disparities in Eye Care—The Time Is Now. *JAMA Ophthalmology* 2021, 139: 935-936. [PMID: 34351375](#), [DOI: 10.1001/jamaophthalmol.2021.2053](#).
23. **Nwanyanwu K**, Scott AW, Elam AR. Addressing Disparities in Ophthalmic Research. *JAMA Ophthalmology* 2021, 139: 1261-1262. [PMID: 34673894](#), [DOI: 10.1001/jamaophthalmol.2021.4203](#).
24. **Nwanyanwu K**. Participatory Science—The Path Toward Health Equity. *JAMA Ophthalmology* 2022, 140: 132-133. [PMID: 34913957](#), [DOI: 10.1001/jamaophthalmol.2021.5368](#).
25. Elam AR, **Nwanyanwu KH**, Scott AW. Elevating Social Determinants of Health and Community Engagement in Eye Care—The Time Is Now. *JAMA Ophthalmology* 2022, 140: 453-454. [PMID: 35323858](#), [DOI: 10.1001/jamaophthalmol.2022.0409](#).
26. Greig EC, Gonzalez-Colaso R, **Nwanyanwu K**. Racial, Ethnic, and Socioeconomic Disparities Drive Appointment No-Show in Patients with Chronic Eye Disease. *Journal Of Racial And Ethnic Health Disparities* 2022, 10: 1790-1797. [PMID: 35864353](#), [PMCID: PMC10392104](#), [DOI: 10.1007/s40615-022-01363-x](#).
27. Dhodapkar RM, Li E, **Nwanyanwu K**, Adelman R, Krishnaswamy S, Wang JC. Deep learning for quality assessment of optical coherence tomography angiography images. *Scientific Reports* 2022, 12: 13775. [PMID: 35962007](#), [PMCID: PMC9374672](#), [DOI: 10.1038/s41598-022-17709-8](#).
28. Baxter SL, **Nwanyanwu K**, Legault G, Lee AY. Data Sources for Evaluating Health Disparities in Ophthalmology Where We Are and Where We Need to Go. *Ophthalmology* 2022, 129: e146-e149. [PMID: 36058733](#), [PMCID: PMC9509471](#), [DOI: 10.1016/j.ophtha.2022.06.035](#).
29. Legault G, **Nwanyanwu K**, Baxter S. Data Sciences and Visual Health Disparities. *Ophthalmology* 2022, 129: 1085-1086. [PMID: 36058740](#), [DOI: 10.1016/j.ophtha.2022.06.032](#).
30. Freedman IG, Li E, Hui L, Adelman RA, **Nwanyanwu K**, Wang JC. The Impact of Image Processing Algorithms on Optical Coherence Tomography Angiography Metrics and Study Conclusions in Diabetic Retinopathy. *Translational Vision Science & Technology* 2022, 11: 7. [PMID: 36107113](#), [PMCID: PMC9483236](#), [DOI: 10.1167/tvst.11.9.7](#).
31. Elam AR, Tseng VL, Rodriguez TM, Mike EV, Warren AK, Coleman AL, American Academy of Ophthalmology Taskforce on Disparities in Eye Care. Disparities in Vision Health and Eye Care. *Ophthalmology* 2022, 129: e89-e113. [PMID: 36058735](#), [DOI: 10.1016/j.ophtha.2022.07.010](#).
32. Andoh J, Ezekwesili A, **Nwanyanwu K**, Elam A. Disparities in Eye Care Access and Utilization: A Narrative Review. *Annual Review Of Vision Science* 2023, 9: 15-37. [PMID: 37254050](#), [DOI: 10.1146/annurev-vision-112122-020934](#).
33. Andoh J, Mehta S, Chen E, Mir T, **Nwanyanwu K**, Teng C. Domestic Violence-Related Ocular Injuries Among Adult Patients: Data from the Nationwide Emergency Department Sample, 2008–

2017. *Ophthalmic Epidemiology* 2023, 31: 169-177. [PMID: 37345877](#) , [PMCID: PMC10739625](#) , [DOI: 10.1080/09286586.2023.2222792](#) .
34. Andoh J, Mir T, Teng C, Wang E, **Nwanyanwu K** . Factors Associated With Visual Impairment Among Adults With a History of Criminal Justice Involvement. *Journal Of Correctional Health Care* 2023, 29: 329-337. [PMID: 37733299](#) , [DOI: 10.1089/jchc.22.07.0056](#) .
35. Andoh J, Miguez S, Andoh S, Mehta S, Mir T, Chen E, Jain S, Teng C, **Nwanyanwu K** . Epidemiologic trends of domestic violence–related ocular injuries among pediatric patients: data from the Nationwide Emergency Department Sample 2008-2017. *Journal Of American Association For Pediatric Ophthalmology And Strabismus* 2023, 27: 335.e1-335.e8. [PMID: 37931837](#) , [PMCID: PMC10859911](#) , [DOI: 10.1016/j.jaapos.2023.09.008](#) .
36. Ahmed O, Applebaum S, Ahmad M, Ahmed D, Juthani P, **Nwanyanwu K** . Needs assessment and patient-guided development of a video-based diabetic retinopathy patient education tool. *Health Education Journal* 2024, 83: 587-597. [DOI: 10.1177/00178969241258818](#) .
37. Owete A, Ionin R, Huryn L, Cukras C, Blain D, Agather A, Hufnagel R, Brooks B, **Nwanyanwu K** , Zein W. Seeing in Color: Inclusion and Characterization of Hereditary Eye Disease in African Americans. *Translational Vision Science & Technology* 2024, 13: 4. [PMID: 39226063](#) , [PMCID: PMC11373706](#) , [DOI: 10.1167/tvst.13.9.4](#) .
38. Woodward MA, Hicks PM, Harris-Nwanyanwu K, Modjtahedi B, Chan RVP, Vogt EL, Lu MC, Newman-Casey PA, American Academy of Ophthalmology Taskforce on Ophthalmology and Community Health Centers. Eye Care in Federally Qualified Health Centers. *Ophthalmology* 2024, 131: 1225-1233. [PMID: 38697267](#) , [DOI: 10.1016/j.opthta.2024.04.019](#) .